Company intelligence
Sano Genetics
Accelerating the world's transition to precision medicine.
About Sano Genetics
At Sano, our mission is to accelerate the world's transition to precision medicine. Sano combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine teams driving breakthroughs for patients.
Verified activity
Signals from Sano Genetics
6 published signals
Showing the latest saved company activity while the live feed reconnects.
Research & Knowledge
Sano Genetics notes that a new ResearchAndMarkets forecast places the decentralized clinical trial technology platform market at $3.37B in 2026, up from $2.9B the year before, reaching $6.12B by 2030 at roughly a 16% CAGR.
Reported by Benjamin Jackson
Research & Knowledge
Sano Genetics wrote about how the shift from treating rare disease trials as fixed costs of one study to infrastructure across programs and years changes the financial aspect of rare disease development.
Reported by Sano Genetics
Presence & Recognition
Sano Genetics hosted Episode 255 of The Genetics Podcast featuring Patrick and Dr. Danny Miller discussing long-read sequencing, building a long-read reference dataset, and genome-informed care.
Reported by Sano Genetics
Legal & Regulatory
Sano Genetics notes that the FDA recently opened the door a little wider for drugs to reach approval on a single clinical trial, with new draft guidance clarifying when a well-controlled trial can be enough to prove a drug works.
Reported by Sano Genetics
Research & Knowledge
Sano Genetics published a study in the Tufts Center for the Study of Drug Development report showing that 70% of site staff said trials have become more difficult to manage.
Reported by Sano Genetics
Customers & Market
Sano Genetics implemented pre-screening and a virtual waiting-room to qualify eligible patients before they reach a clinical trial site.
Reported by Benjamin Jackson